Ampac partners with Inabata and Codexis; Codexis teams with Dishman

By Gareth Macdonald

- Last updated on GMT

Related tags Contract manufacturing organisation Industry

Contract API maker Ampac Fine chemicals (AFC) has had a busy 24-hours, entering the Japanese market through a deal with Inabata and forging an alliance with Codexis on biocatalyst technology.

First up, Japan; the deal with Inabata’s chemicals division allows the US contract manufacturing organisation (CMO) to access what is still one of the world’s most lucrative pharmaceutical markets.

The plan is to use its new Japanese partner’s knowledge of the local pharmaceutical manufacturing sector to find customers for AFC’s range of production technologies, as company president, Aslam Malik, explained.

“[Inabata] have a strong track record of successfully pairing technologies with client needs and know the Japanese marketplace well. Based on their years of experience, they have the ability to identify Japanese partners​.”

In return, Inabata intends to leverage AFC’s technologies for its own customers’ API manufacturing operations, especially during industrial scale-up and commercialisation.

Company general manager Seikou Kuroutsu highlighted AFC’s expertise in simulated moving bed separation (SMB), energetic chemistry and HPAPI production as being key strengths.

Codexis’ biocatalysts

Production technology was also a core focus of the accord with fellow US group Codexis. The deal, also announced yesterday, will see Codexis’ apply its range of proprietary biocatalyst technologies in AFC’s portfolio.

Codexis which, like AFC is also based in California, said application of its technologies will help its new partner reduce cost, increase manufacturing efficiency and lessen environmental impact.

The process optimisation specialist also signed a deal with contract research and manufacturing services (CRAMS) Dishman that sees the Indian firm become its preferred manufacturing partner.

The US firm explained that Dishman “will work exclusively to supply intermediates and active ingredients manufactured using Codexis technology to a select group of innovators​.”

Codexis CEO Alan Shaw said the deals bring its “technology to an expanded portfolio of innovator pharmaceutical products. They will be important as we continue to serve our pharmaceutical customers worldwide​."

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 09-Jun-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.